The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

OS Therapies (OSTX) up 65% in premarket trading after positive phase 2b data on OST-HER2 for lung metastatic osteosarcoma ...

OS Therapies’ (NYSE:OSTX – Get Free Report) lock-up period is set to expire on Tuesday, January 28th. OS Therapies had issued ...

Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...

In recent trading, OS Therapies Inc (OSTX) stock price has shown some volatility, fluctuating -11.02% over the last five trades and -2.24% over the past 30 trades. This represents a notable shift from ...

Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The ...

OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a ...

On Friday, OS Therapies Inc (OSTX) stock saw a decline, ending the day at $2.95 which represents a decrease of $-1.17 or -28.40% from the prior close of $4.12. The stock opened at $4.09 and touched a ...

OS Therapies’s HER2-immunotherapy met the primary endpoint in a Phase IIb trial in patients with recurrent, fully resected, lung metastatic (METS) osteosarcoma. The Phase IIb trial (NCT04974008 ...

OS Therapies (OSTX) announced data from a Phase 2b clinical trial of OST-HER2 – the company’s HER2-targeted immunotherapy candidate in the rare ...

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.